valproic acid and Psychoses studies

Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.

Research Excerpts

Excerpt	Relevance	Reference
"Data on age, gender, race, diagnosis, family history of diabetes, and age at clozapine initiation were collected from medical records of 82 outpatients with schizophrenia or schizoaffective disorder."	9.09	Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. ( Cagliero, E; Goff, DC; Gray, C; Hayden, DL; Henderson, DC; Nasrallah, RA; Schoenfeld, DA, 2000)
" Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation."	8.98	Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Ahmed, U; Hussein, M; Miramontes, K; Ostinelli, EG; Rehman, FU, 2018)
"The aim of this study was to investigate and compare the incidence of suspected or definite cases of clozapine induced myocarditis (SDM) and clinical factors which could influence its onset in two different time periods, defined by pre- and post-cardiac monitoring at an inpatient setting, during the initiation phase of clozapine treatment."	7.91	A comparative study of detection of myocarditis induced by clozapine: With and without cardiac monitoring. ( Ağaoğlu, E; Ak, S; Anıl Yağcıoğlu, AE; Ertuğrul, A; Karahan, S; Karakaşlı, AA; Yazıcı, MK, 2019)
"7%) developed clozapine-induced fever."	7.74	The incidence and characteristics of clozapine- induced fever in a local psychiatric unit in Hong Kong. ( Chan, WF; Chung, KF; Lai-wah Dunn, E; Pui-yin Chung, J; Shiu-yin Chong, C; Wai-nang Tang, O, 2008)
"Subsets of psychiatric patients gain excess body weight while receiving mood-stabilizing agents such as lithium carbonate or valproate sodium."	7.71	Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. ( Brar, JS; Chalasani, L; Chengappa, KN; Houck, P; Levine, J; Parepally, H, 2002)
"A patient with schizoaffective disorder developed signs of catatonia while on a regimen of valproic acid, sertraline, and risperidone."	7.70	Catatonia-like events after valproic acid with risperidone and sertraline. ( Lauterbach, EC, 1998)
"The charts of 55 patients receiving clozapine and valproate concurrently between May 8, 1989, and May 8, 1992, were reviewed to determine the indication for and length of time on each medication, abnormalities in liver function test results, blood cell dyscrasias, seizures, nausea, vomiting, sedation, sialorrhea, and enuresis."	7.69	Concurrent use of clozapine and valproate in affective and psychotic disorders. ( Castillo, J; Centorrino, F; Kando, JC; Tohen, M, 1994)
"Topiramate is an antiepileptic drug, recently also used in the treatment of psychiatric diseases."	5.33	Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. ( Gaudreau, PO; Gobbi, G; Leblanc, N, 2006)
"Lamotrigine (LTG) is a novel antiepileptic drug effective in partial and generalized seizures."	5.31	Stevens-Johnson syndrome associated with concomitant use of lamotrigine and valproic acid. ( Karaduman, A; Yalçin, B, 2000)
"This study compares the metabolic effects of olanzapine and risperidone in a prospective, randomized, open-label trial in 160 patients with DSM-IV-TR schizophrenia, schizoaffective disorder, or bipolar disorder after 1, 3, 6, and 12 months' treatment."	5.15	A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. ( Bobo, WV; Bonaccorso, S; Chen, Y; Jayathilake, K; Meltzer, HY, 2011)
", who received at least 6 weeks of add-on olanzapine treatment for psychotic mood disorders (schizoaffective disorders [bipolar and depressive type], bipolar disorders [I, II, and NOS], and major depressive disorder)."	5.09	Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. ( Grace, JJ; Narendran, R; Pato, MT; Pristach, CA; Valenti, AM; Young, CM, 2001)
"Data on age, gender, race, diagnosis, family history of diabetes, and age at clozapine initiation were collected from medical records of 82 outpatients with schizophrenia or schizoaffective disorder."	5.09	Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. ( Cagliero, E; Goff, DC; Gray, C; Hayden, DL; Henderson, DC; Nasrallah, RA; Schoenfeld, DA, 2000)
"Thirty-five patients, all with major depressive illness, bipolar disorder, or schizoaffective disorder, were retrospectively identified as having received valproate either alone or in combination with lithium, after having failed to adequately respond to previous lithium and/or carbamazepine treatment."	5.06	Long-term use of valproate in primary psychiatric disorders. ( Hayes, SG, 1989)
" Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation."	4.98	Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Ahmed, U; Hussein, M; Miramontes, K; Ostinelli, EG; Rehman, FU, 2018)
"Valproic acid is a widely-used first-generation antiepileptic drug, prescribed predominantly in epilepsy and psychiatric disorders."	4.89	Adverse drug reactions induced by valproic acid. ( Nanau, RM; Neuman, MG, 2013)
" The most often off-label prescribed drugs were quetiapine and mirtazapine for organic mental disorders (F0/G3), valproate and quetiapine in patients with disorders due to psychoactive substance use (F1), valproate in patients with psychotic disorders (F2), and risperidone and olanzapine in patients with affective disorders (F3)."	4.12	Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry. ( Hefner, G; Klimke, A; Reißner, P; Toto, S; Wolff, J, 2022)
"The aim of this study was to investigate and compare the incidence of suspected or definite cases of clozapine induced myocarditis (SDM) and clinical factors which could influence its onset in two different time periods, defined by pre- and post-cardiac monitoring at an inpatient setting, during the initiation phase of clozapine treatment."	3.91	A comparative study of detection of myocarditis induced by clozapine: With and without cardiac monitoring. ( Ağaoğlu, E; Ak, S; Anıl Yağcıoğlu, AE; Ertuğrul, A; Karahan, S; Karakaşlı, AA; Yazıcı, MK, 2019)
"7%) developed clozapine-induced fever."	3.74	The incidence and characteristics of clozapine- induced fever in a local psychiatric unit in Hong Kong. ( Chan, WF; Chung, KF; Lai-wah Dunn, E; Pui-yin Chung, J; Shiu-yin Chong, C; Wai-nang Tang, O, 2008)
"Subsets of psychiatric patients gain excess body weight while receiving mood-stabilizing agents such as lithium carbonate or valproate sodium."	3.71	Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. ( Brar, JS; Chalasani, L; Chengappa, KN; Houck, P; Levine, J; Parepally, H, 2002)
"A patient with schizoaffective disorder developed signs of catatonia while on a regimen of valproic acid, sertraline, and risperidone."	3.70	Catatonia-like events after valproic acid with risperidone and sertraline. ( Lauterbach, EC, 1998)
"The charts of 55 patients receiving clozapine and valproate concurrently between May 8, 1989, and May 8, 1992, were reviewed to determine the indication for and length of time on each medication, abnormalities in liver function test results, blood cell dyscrasias, seizures, nausea, vomiting, sedation, sialorrhea, and enuresis."	3.69	Concurrent use of clozapine and valproate in affective and psychotic disorders. ( Castillo, J; Centorrino, F; Kando, JC; Tohen, M, 1994)
"Agitation and psychosis are common in Alzheimer disease and cause considerable morbidity."	2.76	Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. ( Aisen, PS; Bartocci, B; Cummings, J; Fleisher, A; Ismail, MS; Jack, CR; Jakimovich, LJ; Loy, R; Porsteinsson, A; Raman, R; Schneider, LS; Tariot, PN; Thal, L; Thomas, RG; Weiner, M, 2011)
"Mean weight gain was 10."	2.70	Quetiapine alone and added to a mood stabilizer for serious mood disorders. ( Bingham, CR; Brescan, DW; DiGiovanni, SK; Hattab, H; Perez, DE; Ray, JB; Sajatovic, M, 2001)
"With valproic acid, there was a minor increase in total clozapine metabolites, which was even less with dose correction."	2.67	Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. ( Baldessarini, RJ; Centorrino, F; Flood, JG; Frankenburg, FR; Kando, J; Puopolo, PR; Volpicelli, SA, 1994)
"Cyclical menstrual psychosis is an uncommon, generally a self-limiting mental illness that occurs only in females."	2.58	An Interesting Presentation About Cyclical Menstrual Psychosis with an Updated Review of Literature. ( Birur, B; Cohen, AW; Nagaraja, S; Thippaiah, SM, 2018)
"Pregnancy was a strong determinant for discontinuation of psychotropic medication."	2.53	Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records. ( Cowen, PJ; Evans, SJ; Freemantle, N; McCrea, RL; Nazareth, I; Osborn, DP; Petersen, I; Sammon, CJ, 2016)
"Clinicians and caregivers need to be aware of potential endocrine and metabolic adverse effects of psychiatric medications."	2.43	Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. ( Carlson, HE; Correll, CU, 2006)
"Agents introduced for the treatment of epilepsy have also been usedsimultaneously for psychiatric indications."	2.43	[Anticonvulsants treatment of psychiatric disorder in elderly patients]. ( Bidzan, L, 2006)
"Schizoaffective disorder is a common, chronic, and frequently disabling psychiatric disorder."	2.39	New developments in the pharmacologic treatment of schizoaffective disorder. ( Keck, PE; McElroy, SL; Strakowski, SM, 1996)
"The rate of severe PD-related hair loss was very low in the present survey."	1.48	Severe hair loss associated with psychotropic drugs in psychiatric inpatients-Data from an observational pharmacovigilance program in German-speaking countries. ( Bleich, S; Burda, K; Druschky, K; Frieling, H; Grohmann, R; Hillemacher, T; Neyazi, A; Stübner, S; Toto, S, 2018)
"People with schizophrenia are at greater risk for cardiovascular disease and their overall mortality rate is elevated compared to the general population."	1.43	Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder. ( Greene, CM; Henderson, DC; Jackson, JW; Parnarouskis, L; Ulloa, M; Vincenzi, B, 2016)
"Co-morbid substance abuse was uncommon."	1.39	Prevalence and clinical presentation of HIV positive female psychiatric inpatients. ( Uys, H, 2013)
"Participants with bipolar I or schizoaffective disorder in this study were receiving complex medication treatments that were often discordant with recommendations made in contemporary major treatment guidelines."	1.38	Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice. ( Berk, L; Berk, M; Brnabic, AJ; de Castella, A; Dodd, S; Filia, K; Filia, S; Fitzgerald, PB; Kelin, K; Kulkarni, J; Lowry, AJ; Montgomery, W, 2012)
"The dominant patient was diagnosed with schizoaffective disorder and her non-dominant sister with paranoid schizophrenia."	1.37	Folie à deux: double case-report of shared delusions with a fatal outcome. ( Di Cosimo, D; Girardi, N; Kotzalidis, GD; Lazanio, S; Manfredi, G; Savoja, V; Talamo, A; Tatarelli, R; Vento, A, 2011)
"Whilst post-ictal psychosis is rarely reported prior to the age of 16, NPC in adolescents and adults is particularly psychotogenic and may increase the risk for post-ictal psychosis in the pediatric population."	1.36	Post-ictal psychosis in adolescent Niemann-Pick disease type C. ( Adams, S; Fietz, M; Kornberg, A; Velakoulis, D; Walterfang, M, 2010)
"A large cohort of 1528 patients with parkinsonism was analyzed, gathering data on demography, motor and non-motor characteristics, as well as the final etiologic diagnoses based on established criteria."	1.36	The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. ( Munhoz, RP; Teive, HA; Werneck, LC, 2010)
" Future prospective studies are necessary to clarify whether the prescribed dosage should be different in young and older patients."	1.34	Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. ( Aichhorn, W; Hinterhuber, H; Kemmler, G; Marksteiner, J; Stuppaeck, C; Walch, T; Zernig, G, 2007)
"Topiramate is an antiepileptic drug, recently also used in the treatment of psychiatric diseases."	1.33	Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. ( Gaudreau, PO; Gobbi, G; Leblanc, N, 2006)
"Cotard's syndrome is another rare condition in which the patient has nihilistic delusions and ideation of immortality."	1.33	Co-existence of lycanthropy and Cotard's syndrome in a single case. ( Nejad, AG; Toofani, K, 2005)
"We have observed acute dystonias in the absence of antipsychotic treatment and in the context of seizure activity (or paroxysmal dyskinetic activity)."	1.33	High vulnerability to acute dystonic reactions: a case of antipsychotic exposure and uncontrolled seizure activity. ( Botts, SR; Coffey, GL; de Leon, J, 2005)
"On treatment with olanzapine, valproic acid, and perazine there was only moderate improvement."	1.33	Acute psychosis with a mediastinal carcinoma metastasis. ( Connemann, BJ; Freudenmann, RW; Kassubek, J; Schönfeldt-Lecuona, C; Tumani, H, 2005)
" Coadministration with lithium increased mean Cmax and AUC values of aripiprazole by about 19% and 15%, respectively, whereas the apparent oral clearance decreased by 15%."	1.33	Pharmacokinetics of aripiprazole and concomitant lithium and valproate. ( Bark, N; Citrome, L; Josiassen, R; Mallikaarjun, S; Salazar, DE, 2005)
"Schizoaffective disorder is a common, severe, and lifelong illness; however, little is known about the pharmacologic treatment of this mental disorder."	1.31	Efficacy of divalproex therapy for schizoaffective disorder. ( Bogan, AM; Brown, ES; Suppes, T, 2000)
"Lamotrigine (LTG) is a novel antiepileptic drug effective in partial and generalized seizures."	1.31	Stevens-Johnson syndrome associated with concomitant use of lamotrigine and valproic acid. ( Karaduman, A; Yalçin, B, 2000)
"Patients with a new diagnosis of schizoaffective disorder were stabilized less quickly than those with a previous diagnosis."	1.31	Pharmacologic treatment of hospitalized patients with schizoaffective disorder. ( Benedek, DM; Flynn, J; Grieger, TA, 2002)
" To provide further data on the safety and efficacy of valproate oral loading in the treatment of acute mania, we evaluated 13 consecutive patients with acute manic syndromes who received valproate initiated at a dosage of 20 mg/kg/day."	1.29	Valproate as a loading treatment in acute mania. ( Bennett, JA; Keck, PE; McElroy, SL; Tugrul, KC, 1993)
"Valproic acid was added to the treatment regimens of 21 psychiatric inpatients whose response to antipsychotic medications had been inadequate, and steady-state serum valproate levels were obtained on 15."	1.28	Therapeutic levels of valproate for psychosis. ( Erickson, W; Kluznik, J; Merrill, R; VanValkenburg, C, 1990)
"Valproic acid is infrequently used for treatment of psychosis."	1.28	Neuroleptic-valproic acid combination in treatment of psychotic symptoms: a three-case report. ( Bryant, S; Flack, J; Morrison, P; Wassef, A; Watson, DJ, 1989)

Research

Studies (141)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Basic Activities of Daily Living (BADL)

Timeframe	Studies, this research(%)	All Research%
pre-1990	12 (8.51)	18.7374
1990's	27 (19.15)	18.2507
2000's	58 (41.13)	29.6817
2010's	36 (25.53)	24.3611
2020's	8 (5.67)	2.80

Authors	Studies
Hefner, G	2
Wolff, J	1
Toto, S	2
Reißner, P	1
Klimke, A	1
Tien, Y	1
Suri, R	1
Socol, DK	1
Gitlin, M	1
Bouaziz, N	1
Ben Rejeb, H	1
Ateb, S	1
Fourati, T	1
Chammas, F	1
Baha, D	1
Rosetti, R	1
Kalalou, K	1
Saba, G	1
Benadhira, R	1
Januel, D	1
Lindeman, S	1
Kolari, T	1
Tiihonen, J	1
Colijn, MA	1
Kopel, J	1
Grooms, A	1
Ganapathy, V	1
Clothier, J	1
de Neeling, M	1
van Paesschen, W	1
Womersley, K	1
Hommers, L	1
Scharl, M	1
Hohner, M	1
Fischer, M	1
Pfuhlmann, B	1
Deckert, J	1
Unterecker, S	1
Ostinelli, EG	1
Hussein, M	1
Ahmed, U	1
Rehman, FU	1
Miramontes, K	1
Adams, CE	1
Gawad, NA	1
Kohner, A	1
Ali, T	1
Hofstetter, W	1
Valentine, A	1
Thippaiah, SM	1
Nagaraja, S	1
Birur, B	1
Cohen, AW	1
Thusius, N	1
Romanowicz, M	1
Mlynek, K	1
Sola, C	1
Druschky, K	1
Bleich, S	1
Grohmann, R	1
Burda, K	1
Frieling, H	1
Hillemacher, T	1
Neyazi, A	1
Stübner, S	1
Anıl Yağcıoğlu, AE	1
Ertuğrul, A	1
Karakaşlı, AA	1
Ağaoğlu, E	1
Ak, S	1
Karahan, S	1
Yazıcı, MK	1
Uys, H	1
Nanau, RM	1
Neuman, MG	1
Sarlon, J	1
Hess, E	1
Krasnianski, A	1
Markovic, J	1
Plestic, S	1
Kostic, J	1
Verma, R	1
Junewar, V	1
Rathaur, BP	1
Dubovsky, SL	1
Daurignac, E	1
Leonard, KE	1
Pinacho, R	1
Saia, G	1
Fusté, M	1
Meléndez-Pérez, I	1
Villalta-Gil, V	1
Haro, JM	1
Gill, G	1
Ramos, B	1
Al-sharefi, A	1
Bilous, R	1
Tseng, PT	1
Chen, YW	1
Chung, W	1
Tu, KY	1
Wang, HY	1
Wu, CK	1
Lin, PY	1
Petersen, I	1
McCrea, RL	1
Sammon, CJ	1
Osborn, DP	1
Evans, SJ	1
Cowen, PJ	1
Freemantle, N	1
Nazareth, I	1
Vincenzi, B	1
Greene, CM	1
Ulloa, M	1
Parnarouskis, L	1
Jackson, JW	1
Henderson, DC	2
Moyal, D	1
Sanyal, S	1
Khanna, A	1
Susser, LC	1
Hermann, AD	1
Gandolfo, F	1
Parodi, MN	1
Corsini, GP	1
Odetti, P	1
Serafini, G	1
Monacelli, F	1
Kanofsky, JD	1
Woesner, ME	1
Xiong, GL	1
Ferranti, J	1
Leamon, MH	1
Nunes, A	1
Ohadi, M	1
Rahimi, A	1
Aghajani, A	1
Najmabadi, H	1
Currais, A	1
Soriano, S	1
Nixon, AC	1
Doak, MW	1
Crozier, H	1
Crooks, DP	1
Waring, WS	1
Caetano, D	1
Bini, P	1
Montalbetti, L	1
Tosca, P	1
Ratti, MT	1
Uggetti, C	1
Moglia, A	1
Costa, A	1
Pui-yin Chung, J	1
Shiu-yin Chong, C	1
Chung, KF	1
Lai-wah Dunn, E	1
Wai-nang Tang, O	1
Chan, WF	1
Reiche, I	1
Tröger, U	1
Postel, SC	1
Wolf, R	1
Bode-Böger, SM	1
Patterson, JV	1
Sandman, CA	1
Ring, A	1
Jin, Y	1
Bunney, WE	1
Spina, E	1
D'Arrigo, C	1
Santoro, V	1
Muscatello, MR	1
Pandolfo, G	1
Zoccali, R	1
Diaz, FJ	1
de Leon, J	2
Walterfang, M	1
Kornberg, A	1
Adams, S	1
Fietz, M	1
Velakoulis, D	1
Chou, JC	1
Munhoz, RP	1
Werneck, LC	1
Teive, HA	1
Belaizi, M	1
Mehssani, J	1
Yahyaoui, M	1
Fajri, A	1
Ventriglio, A	1
Vincenti, A	1
Centorrino, F	4
Talamo, A	2
Fitzmaurice, G	1
Baldessarini, RJ	3
Vento, A	1
Savoja, V	1
Di Cosimo, D	1
Lazanio, S	1
Kotzalidis, GD	1
Manfredi, G	1
Girardi, N	1
Tatarelli, R	1
Tariot, PN	1
Schneider, LS	1
Cummings, J	1
Thomas, RG	1
Raman, R	1
Jakimovich, LJ	1
Loy, R	1
Bartocci, B	1
Fleisher, A	1
Ismail, MS	1
Porsteinsson, A	1
Weiner, M	1
Jack, CR	1
Thal, L	1
Aisen, PS	1
Meltzer, HY	1
Bonaccorso, S	1
Bobo, WV	1
Chen, Y	1
Jayathilake, K	1
Turan, AB	1
Seferoglu, M	1
Taskapilioglu, O	1
Bora, I	1
Kaur, M	1
Marawar, R	1
Ritaccio, A	1
Hong, L	1
Schutz, J	1
Nance, M	1
Sotoing Taïwe, G	1
Ngo Bum, E	1
Talla, E	1
Dawe, A	1
Okomolo Moto, FC	1
Temkou Ngoupaye, G	1
Sidiki, N	1
Dabole, B	1
Djomeni Dzeufiet, PD	1
Dimo, T	1
De Waard, M	1
Uz, Y	1
Hariri, A	1
Ünübol, H	1
Bilici, M	1
Kulkarni, J	2
Filia, S	1
Berk, L	1
Filia, K	1
Dodd, S	2
de Castella, A	1
Brnabic, AJ	1
Lowry, AJ	1
Kelin, K	2
Montgomery, W	2
Fitzgerald, PB	2
Berk, M	2
Chengappa, KN	1
Chalasani, L	1
Brar, JS	1
Parepally, H	1
Houck, P	1
Levine, J	2
Kelleher, JP	1
Berry, JM	1
Salvatore, P	1
Eakin, M	1
Fogarty, KV	1
Fellman, V	1
Raja, M	1
Azzoni, A	1
Roepke, S	1
Treudler, R	1
Anghelescu, I	1
Orfanos, CE	1
Tebbe, B	1
Jaffe, R	1
Leavitt, R	1
Wind, T	1
Stahl, SM	1
Jacquet, H	1
Demily, C	1
Houy, E	1
Hecketsweiler, B	1
Bou, J	1
Raux, G	1
Lerond, J	1
Allio, G	1
Haouzir, S	1
Tillaux, A	1
Bellegou, C	1
Fouldrin, G	1
Delamillieure, P	1
Ménard, JF	1
Dollfus, S	1
D'Amato, T	1
Petit, M	1
Thibaut, F	1
Frébourg, T	1
Campion, D	1
Citrome, L	2
Josiassen, R	1
Bark, N	1
Salazar, DE	1
Mallikaarjun, S	1
Schönfeldt-Lecuona, C	1
Freudenmann, RW	1
Tumani, H	1
Kassubek, J	1
Connemann, BJ	1
Veldic, M	1
Guidotti, A	1
Maloku, E	1
Davis, JM	1
Costa, E	1
Nejad, AG	1
Toofani, K	1
Mayerhoff, DI	1
Nurenberg, J	1
Shah, S	1
Schleifer, SJ	1
Junig, JT	1
Lehrmann, JA	1
Coffey, GL	1
Botts, SR	1
Chae, BJ	1
Kang, BJ	1
Longo, LP	1
Chan, YC	1
Miller, KM	1
Shaheen, N	1
Votolato, NA	1
Hankins, MB	1
Yohanan, M	1
Aulakh, JS	1
Weith, J	1
Hawkins, JW	1
Awad, AG	1
Correll, CU	1
Carlson, HE	1
Gobbi, G	1
Gaudreau, PO	1
Leblanc, N	1
Bidzan, L	1
Kanai, K	1
Sakakibara, R	1
Uchiyama, T	1
Liu, Z	1
Yamamoto, T	1
Ito, T	1
Hirano, S	1
Asahina, M	1
Kuwabara, S	1
Hattori, T	1
Fukami, G	1
Arai, K	1
Yamaguchi, C	1
Nomura, F	1
Otsuka, K	1
Sakai, A	1
Okudera, T	1
Shibata, E	1
Matoh, K	1
Kawamura, S	1
Reeves, RR	2
Burke, RS	1
Parker, JD	1
Carr, RB	1
Shrewsbury, K	1
Duggal, HS	1
Yerevanian, BI	1
Koek, RJ	1
Mintz, J	1
Habermeyer, B	2
Rabovsky, K	2
Jentzsch, C	1
Pinhard, K	1
Pinard, K	1
Müller-Spahn, F	1
Kashia, VSh	1
Bandzeladze, LG	1
Nioradze, EG	1
Tkeshelashvili, NM	1
Tsitlidze, LM	1
de Castella, AR	1
Brnabic, A	1
Granger, RE	1
Aichhorn, W	1
Marksteiner, J	1
Walch, T	1
Zernig, G	1
Hinterhuber, H	1
Stuppaeck, C	1
Kemmler, G	1
Hess, M	1
Kozomara-Hocke, P	1
Mager, R	1
Kawohl, W	1
Cesková, E	1
Svestka, J	1
Obrovská, V	1
Rysánek, R	1
Náhunek, K	1
Saito, M	1
Inoue, R	1
Friis, T	1
Christensen, TR	1
Gerlach, J	1
Puzyński, S	2
Kłosiewicz, L	2
von Zerssen, D	1
Emrich, HM	1
Puryear, LJ	1
Kunik, ME	1
Molinari, V	1
Workman, RH	1
Costello, LE	1
Suppes, T	4
Guthrie, SK	1
Stoysich, AM	1
Bader, G	1
Hilleman, DE	1
Stoll, AL	1
Banov, M	1
Kolbrener, M	1
Mayer, PV	1
Tohen, M	4
Strakowski, SM	3
Castillo, J	4
Cohen, BM	1
Kando, JC	2
Pope, HG	2
Herbstein, J	1
McElroy, SL	4
Keck, PE	4
Tugrul, KC	1
Bennett, JA	1
Schaff, MR	1
Fawcett, J	1
Zajecka, JM	1
Kando, J	1
Frankenburg, FR	1
Volpicelli, SA	1
Puopolo, PR	1
Flood, JG	1
Fenn, HH	1
Robinson, D	1
Luby, V	1
Dangel, C	1
Buxton, E	1
Beattie, M	1
Kraemer, H	1
Yesavage, JA	1
Zarate, CA	1
Rush, AJ	1
Hammer, BA	1
Brady, KT	1
Reutens, S	1
Castle, D	1
Deltito, JA	1
Levitan, J	1
Damore, J	1
Hajal, F	1
Zambenedetti, M	1
Lauterbach, EC	1
Allingham, B	1
Waring, EW	1
Dewan, VK	1
Cohen, D	1
Grewal, R	1
Hesslinger, B	1
Normann, C	1
Langosch, JM	1
Klose, P	1
Berger, M	1
Walden, J	1
Panikkar, GP	1
Gilman, SM	1
Davis, LL	1
Ryan, W	1
Adinoff, B	1
Petty, F	1
Cagliero, E	1
Gray, C	1
Nasrallah, RA	1
Hayden, DL	1
Schoenfeld, DA	1
Goff, DC	1
Bogan, AM	1
Brown, ES	1
Yalçin, B	1
Karaduman, A	1
DelBello, MP	1
Lopez-Larson, MP	1
Getz, GE	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Treatment of Psychosis and Agitation in Alzheimer's Disease[NCT02129348]	Phase 2	77 participants (Actual)	Interventional	2014-06-30	Completed
A Randomized, Double-Blind, Placebo-Controlled Trial of Valproate to Attenuate the Progression of Alzheimer's Disease (AD)[NCT00071721]	Phase 3	313 participants (Actual)	Interventional	2003-10-31	Completed
Effects of Risperidone and Olanzapine on Weight Gain, Physical Health, and Outcome in a Community Sample of Severity and Persistently Ill Patients[NCT00179062]		300 participants (Actual)	Interventional	2000-02-29	Completed
1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700]	Phase 4	14 participants (Actual)	Interventional	2013-07-31	Terminated (stopped due to very slow recruitment, no sufficient results)
A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis[NCT00337350]	Phase 4	20 participants (Actual)	Interventional	2003-09-30	Completed
An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000]	Phase 4	24 participants (Actual)	Interventional	2005-01-31	Completed
Aripiprazole for Clozapine Associated Medical Morbidity[NCT00345033]	Phase 4	38 participants (Actual)	Interventional	2005-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Basic Activities of Daily Living with items for 6 functions: bathing, dressing, toileting, transferring, continence, and feeding. Each item is scored as unimpaired=1, impaired=0. Total score is the measure used, range 0-6; higher scores indicate better functioning. (NCT02129348)
Timeframe: Assessed at Week 0, Week2, Week 4, Week 6, Week 8, Week 10, Week 12

Change in Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	0.3
Placebo Group	0.1

Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain is the measure used that combines symptoms of agitation and aggression. Frequency X Severity rating score, range 0-12. Higher score indicates more agitation and aggressive behavior. (NCT02129348)
Timeframe: Assessed at screening, Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12

Clinical Global Impression (CGI) Behavior Change

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	3.2
Placebo Group	2.5

Clinical Global Impression (CGI) Behavior Change score is the measure used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Scores ranging from 1-3 indicate improvement. Only patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12

Clinical Responder Defined as a 30% Decrease in NPI Core Score (Sum Score of NPI Domains of Agitation/Aggression, Delusions and Hallucinations) Together With a Clinical Global Impression (CGI) Behavior Change Score of 1 or 2

Intervention	Participants (Count of Participants)
Lithium Treatment Group	12
Placebo Group	8

The patient is classified as a responder (score=1) if both criteria are met or as a non-responder (score=0) if both criteria are not met. The first criterion to determine responder status, NPI core score, has a scoring range 0-36; each of the three component scores for symptoms of agitation/aggression, delusions and hallucinations has a scoring range 0-12. For each symptom and the total score, higher score indicates more symptoms. The second criterion to determine responder status, Clinical Global Impression (CGI), is used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Only patients who met both criteria, assessed as change compared to baseline, were counted as responders; all other patients were non-responders. Patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12

Folstein Mini-Mental Status Exam

Intervention	Participants (Count of Participants)
Lithium Treatment Group	12
Placebo Group	7

30 item questionnaire used to assess degree of cognitive impairment. Orientation, registration, attention/calculation, recall, language, repetitions and commands are assessed. Total score is the measure used; range 0-30, higher scores indicate better global cognitive function. (NCT02129348)
Timeframe: Assessed at Screening, Week 12

Severe Impairment Battery

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	0.9
Placebo Group	0.9

Neuropsychological test used to assess a patient's cognitive ability. The patient is asked to complete small tasks such as drawing shapes and printing their name. They are also asked to remember certain names and objects, such as a cup and a spoon, and the evaluator's first name. Total score is the measure used; range 0-100, higher scores indicate better cognition. (NCT02129348)
Timeframe: Assessed at Week 0, Week 12

Simpson-Angus Scale

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	2.1
Placebo Group	-0.0

Simpson Angus Scale for Extrapyramidal Sign requires in-person examination to assess gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor, and salivation. Total score is the measure used, range 0-40; higher scores indicate increased severity of signs. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12

Treatment Emergent Signs and Symptoms

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	-0.0
Placebo Group	0.0

Treatment Emergent Symptom Scale that covers 26 somatic symptoms, each rated as present (score=1) or absent (score=0). Total score is the measure used with scoring range 0-26; higher scores indicate more somatic symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12

Young Mania Rating Scale

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	0.6
Placebo Group	0.7

Young Mania Rating Scale total score is the measure used to assess symptoms that occur in mania; each item is a symptom that is rated for severity. Scoring range 0-60; higher scores indicate more severe symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12

Zarit Caregiver Burden Interview

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	3.1
Placebo Group	1.1

Zarit Caregiver Burden Interview with the caregiver asked to rank 22 items on a scale with responses for each item from 'never' (score 0) to 'nearly always' (score 4). Total score is the measure used; range 0-88 with higher scores indicating greater caregiver burden. (NCT02129348)
Timeframe: Assessed at Week 0, Week 4, Week 8, Week 10, Week 12

Agitation Measured by the Cohen-Mansfield Agitation Inventory (CMAI), Community Version

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	2.8
Placebo Group	-0.4

The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item caregiver rating questionnaire for the assessment of agitation in older persons. It includes descriptions of 29 agitated behaviors, each rated on a 7-point scale of frequency. The range of this instrument is 29 to 203 with higher numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months

Cognitive Performance Assessed by the Alzheimer's Disease Assessment Scale-cognitive Subtest (ADAS-cog)

Intervention	Units on a scale (Mean)
Valproate	10.6
Placebo	12.1

Alzheimer's Disease Assessment Scale, cognitive sub-scale in points per year (ADAS-cog) is a psychometric measure sensitive to change in mild to moderate AD. The range of this instrument is 0 to 70 with higher numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months

Functional Performance Assessed by the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory

Intervention	Units on a scale (Mean)
Valproate	42.3
Placebo	41.9

Alzheimer's Disease Cooperative Study Activities of Daily Living Score (ADCS-ADL) is a structured questionnaire about activities of daily living, administered to the subject's caregiver/study partner. The range of this instrument is 0 to 78 with lower numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months

Global Severity of Dementia Using the CDR Sum of Boxes

Intervention	Units on a scale (Mean)
Valproate	35.1
Placebo	41.0

Clinical Dementia Rating, Sum of Boxes (CDR-SOB) is a global rating of dementia severity based on the clinician's interpretation of the history and examination. The range of this instrument is 0 to 18 with higher numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months

Participant's Clinical Condition or Endpoint Assessed With the ADCS-Clinical Global Impression of Change (ADCS-CGIC)

Intervention	Units on a scale (Mean)
Valproate	12.0
Placebo	11.5

ADCS-Clinical Global Impression of Change (ADCS-CGIC) provides a means to reliably assess global change from baseline. It provides a semi-structured format to allow clinicians to gather necessary clinical information from both the participant and informant, in order to make an overall impression of clinical change. The range of this instrument is 1 to 7 with lower numbers indicating improvement and higher numbers indicating a worsened state. (NCT00071721)
Timeframe: 24 months

Presence of Agitation and/or Psychosis Measured by the Neuropsychiatric Inventory (NPI) Combined With an Assessment of the Clinical Significance of Behavioral Change Rated by the Study Clinician

Intervention	Units on a scale (Mean)
Valproate	5.7
Placebo	5.5

NPI quantifies behavioral changes in dementia, including depression, anxiety, psychosis, agitation, and others. This is a questionnaire administered to the subject's study partner. The range of this instrument is 0 to 120 with higher numbers indicating greater impairment. To determine whether or not psychosis or agitation is present, there is no cutoff score but is based on the clinician's judgment. In the NPI, the subject responds to 'Yes' or 'No' questions. Then it is determined how often psychosis or agitation occurs and if it is mild, moderate or severe. (NCT00071721)
Timeframe: 24 months

Percent Weight Change Compared to Baseline Weight

BMI Percentile

BMI Z-scores

Weight Change

Change From Baseline in Acute Insulin Response to Glucose (AIRG)

Intervention	Participants (Number)
Valproate	25
Placebo	29

Intervention	percentage of weight change (Mean)
Ziprasidone	11.58
Aripiprazole, Quetiapine, Risperidone	5.66

Intervention	BMI percentile (Mean)
	baseline	week 12 (n=1, n=2)
Aripiprazole, Quetiapine, Risperidone	37.67	62.5
Ziprasidone	32	59

Intervention	BMI z-score (Mean)
	baseline	week 12 (n=1, n=2)
Aripiprazole, Quetiapine, Risperidone	-0.37	0.38
Ziprasidone	-0.51	0.22

Intervention	lbs (Mean)
	baseline	week 12 (n=1,2)
Aripiprazole, Quetiapine, Risperidone	118.5	141
Ziprasidone	120.5	151

Acute insulin response to glucose (AIRG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. AIRG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. AIRG measures the acute(0-10 min) beta cell response to a glucose load calculated by the areas under the curve higher than basal insulin values. The AIRG was assessed as the incremental area under the curve (calculated by the trapezoid rule) from 0 to 10 min of the FSIVGTT. (NCT00337350)
Timeframe: baseline, week 8

Change From Baseline in Insulin Sensitivity

Intervention	Units/mL per 10 minutes (Mean)
Rosiglitazone	-151
Placebo	19

Insulin Sensitivity (IS) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in IS between Baseline and week 8. SI was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SI represents the increase in net fractional glucose clearance rate per unit change in serum insulin concentration after the intravenous glucose load (microUnits/mL). (NCT00337350)
Timeframe: baseline, week 8

Change From Baseline on Glucose Utilization (SG)

Intervention	microUnits/mL (Mean)
Rosiglitazone	3.2
Placebo	0.4

Glucose utilization (SG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. SG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SG represents the net fractional glucose clearance rate because of the increase in glucose independent of any increase in circulating insulin concentrations above baseline. (NCT00337350)
Timeframe: baseline, week 8

Change From Baseline in Fasting Glucose

Intervention	min^-1 (Mean)
Rosiglitazone	.002
Placebo	-0.01

Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6

Change From Baseline on Fasting Insulin

Intervention	mg/dL (Mean)
Clozapine Treatment With Adjunctive Ziprasidone	5
Olanzapine Treatment With Adjunctive Ziprasidone	-4.5

Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6

Change in Body Mass Index (BMI)

Intervention	microIU/L (Mean)
Clozapine Treatment With Adjunctive Ziprasidone	1
Olanzapine Treatment With Adjunctive Ziprasidone	-0.9

A comparison between aripiprazole group and placebo group of change in Body Mass Index (BMI) measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8

Change in Glucose Metabolism

Intervention	kg/m^2 (Mean)
Aripiprazole	-0.52
Placebo	0.03

A comparison between the aripiprazole group and placebo group in change in glucose metabolism measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8

Change in Insulin Resistance

Intervention	min^-1 (Mean)
Aripiprazole	0.003
Placebo	-0.005

A comparison between aripiprazole group and placebo group of change in insulin resistance measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8

Change in Total Cholesterol

Intervention	HOMA score (Mean)
Aripiprazole	0.6
Placebo	0.65

A comparison of aripiprazole group and placebo group in change in total cholesterol measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8

Change in Triglycerides

Change in Weight

Intervention	mg/dL (Mean)
Aripiprazole	-15.3
Placebo	5.6

Intervention	mg/dL (Mean)
Aripiprazole	-5.9
Placebo	-7.3

A comparison between aripiprazole group and placebo group in change in weight measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8

Article	Year
The characterization of psychotic symptoms in succinic semialdehyde dehydrogenase deficiency: a review. Psychiatric genetics, 2020, Volume: 30, Issue:6 Topics: Adolescent; Age of Onset; Aggression; Amino Acid Metabolism, Inborn Errors; Anticonvulsants; Anxiety	2020
Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). The Cochrane database of systematic reviews, 2018, 04-10, Volume: 4 Topics: Administration, Oral; Aggression; Antipsychotic Agents; Carbamazepine; Humans; Oxcarbazepine; Psycho	2018
An Interesting Presentation About Cyclical Menstrual Psychosis with an Updated Review of Literature. Psychopharmacology bulletin, 2018, 03-13, Volume: 48, Issue:3 Topics: Adult; Female; Humans; Menstruation Disturbances; Psychotic Disorders; Risperidone; Tranquilizing Ag	2018
Adverse drug reactions induced by valproic acid. Clinical biochemistry, 2013, Volume: 46, Issue:15 Topics: Anticonvulsants; Antipsychotic Agents; Drug Hypersensitivity; Endocrine System; Epilepsy; Humans; Hy	2013
Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia: A Meta-analysis Study. Medicine, 2016, Volume: 95, Issue:4 Topics: Anticonvulsants; Antipsychotic Agents; Drug Synergism; Drug Therapy, Combination; Humans; Psychotic	2016
Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records. Health technology assessment (Winchester, England), 2016, Volume: 20, Issue:23 Topics: Adult; Antipsychotic Agents; Drug Utilization; Electronic Health Records; Female; Humans; Infant, Ne	2016
Mixed episodes with psychotic features. CNS spectrums, 2009, Volume: 14, Issue:11 Suppl 1 Topics: Acute Disease; Adult; Affect; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Bipolar Disorder;	2009
Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, Volume: 45, Issue:7 Topics: Adolescent; Antipsychotic Agents; Child; Dibenzothiazepines; Drug Administration Schedule; Endocrine	2006
[Anticonvulsants treatment of psychiatric disorder in elderly patients]. Przeglad lekarski, 2006, Volume: 63, Issue:7 Topics: Aged; Anticonvulsants; Anxiety Disorders; Bipolar Disorder; Carbamazepine; Epilepsy; Humans; Mental	2006
Hyperammonemia due to valproic acid in the psychiatric setting. The American journal of psychiatry, 2007, Volume: 164, Issue:7 Topics: Adult; Aged; Bipolar Disorder; Carnitine; Child; Female; Humans; Hyperammonemia; Liver; Middle Aged;	2007
Treatment guidelines for valproate in bipolar and schizoaffective disorders. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1993, Volume: 38, Issue:3 Suppl 2 Topics: Bipolar Disorder; Depressive Disorder; Drug Monitoring; Humans; Metabolic Clearance Rate; Psychotic	1993
New developments in the pharmacologic treatment of schizoaffective disorder. The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 9 Topics: Antidepressive Agents; Antipsychotic Agents; Carbamazepine; Clinical Trials as Topic; Clozapine; Dru	1996
Comprehensive review of the psychiatric uses of valproate. Journal of clinical psychopharmacology, 2000, Volume: 20, Issue:1 Suppl 1 Topics: Anticonvulsants; Antimanic Agents; Anxiety Disorders; Bipolar Disorder; Depressive Disorder, Major;	2000
New treatments for bipolar disorder: the role of atypical neuroleptic agents. The Journal of clinical psychiatry, 2000, Volume: 61 Suppl 14 Topics: Acute Disease; Algorithms; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazep	2000
U.S. experience with valproate in manic depressive illness: a multicenter trial. The Journal of clinical psychiatry, 1989, Volume: 50 Suppl Topics: Adult; Aged; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder; Humans; Middle Aged; P	1989
Valproate in psychiatric disorders: literature review and clinical guidelines. The Journal of clinical psychiatry, 1989, Volume: 50 Suppl Topics: Bipolar Disorder; Clinical Trials as Topic; Humans; Mental Disorders; Psychotic Disorders; Valproic	1989
[A valproic acid-diazepam combination as an alternative to neuroleptic treatment]. Annales medico-psychologiques, 1988, Volume: 146, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Bipolar Disorder; Diazepam; Drug Combinations; Female; Humans; Male;	1988

Article	Year
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of general psychiatry, 2011, Volume: 68, Issue:8 Topics: Aged; Alzheimer Disease; Atrophy; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Middle Ag	2011
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of general psychiatry, 2011, Volume: 68, Issue:8 Topics: Aged; Alzheimer Disease; Atrophy; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Middle Ag	2011
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of general psychiatry, 2011, Volume: 68, Issue:8 Topics: Aged; Alzheimer Disease; Atrophy; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Middle Ag	2011
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of general psychiatry, 2011, Volume: 68, Issue:8 Topics: Aged; Alzheimer Disease; Atrophy; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Middle Ag	2011
A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. The Journal of clinical psychiatry, 2011, Volume: 72, Issue:12 Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; GABA Agents; Hum	2011
Pilot comparison of extended-release and standard preparations of divalproex sodium in patients with bipolar and schizoaffective disorders. The American journal of psychiatry, 2003, Volume: 160, Issue:7 Topics: Ambulatory Care; Antimanic Agents; Bipolar Disorder; Delayed-Action Preparations; Drug Administratio	2003
Hyperprolinemia is a risk factor for schizoaffective disorder. Molecular psychiatry, 2005, Volume: 10, Issue:5 Topics: Adult; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Case-Control Studies; Chromosomes,	2005
Extended-release divalproex sodium for patients with side effects from delayed-release divalproex sodium. The American journal of psychiatry, 2005, Volume: 162, Issue:8 Topics: Adult; Ambulatory Care; Antimanic Agents; Bipolar Disorder; Delayed-Action Preparations; Drug Admini	2005
[Assessment of depakine treatment of patients with endogen psychosis (clinical trial)]. Georgian medical news, 2007, Issue:147 Topics: Adolescent; Adult; Humans; Male; Middle Aged; Prospective Studies; Psychotic Disorders; Valproic Aci	2007
The Bipolar Comprehensive Outcomes Study (BCOS): baseline findings of an Australian cohort study. Journal of affective disorders, 2008, Volume: 107, Issue:1-3 Topics: Adult; Aged; Anticonvulsants; Antipsychotic Agents; Australia; Benzodiazepines; Bipolar Disorder; Ca	2008
Valproic acid amide in the treatment of affective and schizoaffective disorders. Journal of affective disorders, 1984, Volume: 6, Issue:1 Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as	1984
Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. The American journal of psychiatry, 1994, Volume: 151, Issue:1 Topics: Adult; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Comb	1994
Naturalistic experience with the use of divalproex sodium on an in-patient unit for adolescent psychiatric patients. Acta psychiatrica Scandinavica, 1998, Volume: 97, Issue:3 Topics: Adolescent; Adolescent Psychiatry; Clinical Trials as Topic; Female; Humans; Male; Mood Disorders; P	1998
Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. Journal of clinical psychopharmacology, 1999, Volume: 19, Issue:4 Topics: Adult; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Drug Interactions; Drug Therapy, Combi	1999
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. The American journal of psychiatry, 2000, Volume: 157, Issue:6 Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab	2000
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. The American journal of psychiatry, 2000, Volume: 157, Issue:6 Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab	2000
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. The American journal of psychiatry, 2000, Volume: 157, Issue:6 Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab	2000
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. The American journal of psychiatry, 2000, Volume: 157, Issue:6 Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab	2000
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. The American journal of psychiatry, 2000, Volume: 157, Issue:6 Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab	2000
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. The American journal of psychiatry, 2000, Volume: 157, Issue:6 Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab	2000
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. The American journal of psychiatry, 2000, Volume: 157, Issue:6 Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab	2000
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. The American journal of psychiatry, 2000, Volume: 157, Issue:6 Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab	2000
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. The American journal of psychiatry, 2000, Volume: 157, Issue:6 Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab	2000
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. The American journal of psychiatry, 2000, Volume: 157, Issue:6 Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab	2000
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. The American journal of psychiatry, 2000, Volume: 157, Issue:6 Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab	2000
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. The American journal of psychiatry, 2000, Volume: 157, Issue:6 Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab	2000
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. The American journal of psychiatry, 2000, Volume: 157, Issue:6 Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab	2000
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. The American journal of psychiatry, 2000, Volume: 157, Issue:6 Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab	2000
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. The American journal of psychiatry, 2000, Volume: 157, Issue:6 Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab	2000
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. The American journal of psychiatry, 2000, Volume: 157, Issue:6 Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab	2000
Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. The Journal of clinical psychiatry, 2001, Volume: 62, Issue:7 Topics: Adult; Affective Disorders, Psychotic; Aged; Anticonvulsants; Antipsychotic Agents; Benzodiazepines;	2001
Quetiapine alone and added to a mood stabilizer for serious mood disorders. The Journal of clinical psychiatry, 2001, Volume: 62, Issue:9 Topics: Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Brief Psychiatric Rating Scale; Dibenzothiazepi	2001
[Comparative effectiveness of preventive use of lithium carbonate, carbamazepine and sodium valproate in affective and schizoaffective psychoses]. Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1991, Volume: 91, Issue:4 Topics: Adult; Affective Disorders, Psychotic; Aged; Carbamazepine; Humans; Lithium; Lithium Carbonate; Midd	1991
U.S. experience with valproate in manic depressive illness: a multicenter trial. The Journal of clinical psychiatry, 1989, Volume: 50 Suppl Topics: Adult; Aged; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder; Humans; Middle Aged; P	1989
Valproate in psychiatric disorders: literature review and clinical guidelines. The Journal of clinical psychiatry, 1989, Volume: 50 Suppl Topics: Bipolar Disorder; Clinical Trials as Topic; Humans; Mental Disorders; Psychotic Disorders; Valproic	1989
Long-term use of valproate in primary psychiatric disorders. The Journal of clinical psychiatry, 1989, Volume: 50 Suppl Topics: Adult; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder; Drug Therapy, Combination; F	1989

Article	Year
Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry. Journal of neural transmission (Vienna, Austria : 1996), 2022, Volume: 129, Issue:11 Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Humans; Male; Mental Disorders	2022
Valproic Acid Induced Thrombocytopenia in an Elderly Man with Schizoaffective Disorder: A Case Report. Pharmacopsychiatry, 2023, Volume: 56, Issue:5 Topics: Aged; Humans; Male; Psychotic Disorders; Thrombocytopenia; Valproic Acid	2023
Standard of Care: Reasonable But Not Perfect. The American journal of psychiatry, 2020, 03-01, Volume: 177, Issue:3 Topics: Abnormalities, Drug-Induced; Adult; Arnold-Chiari Malformation; Female; Humans; Hydrocephalus; Infan	2020
[Thoughts on a favourable evolution of a COVID-19 in a patient with resistant schizophrenia and on a combination of clozapine and paliperidone palmitate]. L'Encephale, 2020, Volume: 46, Issue:3S Topics: Anticonvulsants; Antipsychotic Agents; Betacoronavirus; Clozapine; Coronavirus Infections; COVID-19;	2020
Valproate and Neuroleptic Malignant Syndrome in an Elderly Patient With Schizoaffective Disorder. The primary care companion for CNS disorders, 2020, 06-11, Volume: 22, Issue:3 Topics: Aged; Humans; Male; Neuroleptic Malignant Syndrome; Psychotic Disorders; Tranquilizing Agents; Valpr	2020
Metformin, valproic acid, and starvation induce seizures in a patient with partial SLC13A5 deficiency: a case of pharmaco-synergistic heterozygosity. Psychiatric genetics, 2021, 02-01, Volume: 31, Issue:1 Topics: Adult; Amino Acid Substitution; Ammonia; Animals; Anticonvulsants; Autistic Disorder; Bipolar Disord	2021
Stupor in a catatonic patient due to an interaction between high-dose lorazepam and valproic acid: a case report. Acta neurologica Belgica, 2021, Volume: 121, Issue:4 Topics: Adult; Anti-Anxiety Agents; Antimanic Agents; Catatonia; Drug Interactions; Female; Humans; Lorazepa	2021
Prescription of Sodium Valproate as a Mood Stabiliser in Pregnancy. Psychiatria Danubina, 2017, Volume: 29, Issue:Suppl 3 Topics: Bipolar Disorder; Female; Humans; Pregnancy; Pregnancy Complications; Psychotic Disorders; Valproic	2017
Comedication of Valproic Acid Is Associated With Increased Metabolism of Clozapine. Journal of clinical psychopharmacology, 2018, Volume: 38, Issue:3 Topics: Adult; Antimanic Agents; Antipsychotic Agents; Clozapine; Drug Interactions; Drug Monitoring; Female	2018
Valproic Acid Attenuates Postoperative Psychosis Following Aggressive Resection of an Intracardiac Carcinoid Neuroendocrine Tumor: A Case Report. Psychosomatics, 2018, Volume: 59, Issue:6 Topics: Carcinoid Tumor; Female; GABA Agents; Heart Neoplasms; Humans; Middle Aged; Postoperative Complicati	2018
Prolonged Psychosis Associated with Left Insular Stroke: Talking to God in the Walls. Psychosomatics, 2018, Volume: 59, Issue:6 Topics: Aged; Antimanic Agents; Antipsychotic Agents; Cerebral Cortex; Electroencephalography; Hallucination	2018
Severe hair loss associated with psychotropic drugs in psychiatric inpatients-Data from an observational pharmacovigilance program in German-speaking countries. European psychiatry : the journal of the Association of European Psychiatrists, 2018, Volume: 54 Topics: Adult; Alopecia; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Austria; Bipolar Dis	2018
A comparative study of detection of myocarditis induced by clozapine: With and without cardiac monitoring. Psychiatry research, 2019, Volume: 279 Topics: Adult; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Female; Humans; Incidence; Inpati	2019
Prevalence and clinical presentation of HIV positive female psychiatric inpatients. African journal of psychiatry, 2013, Volume: 16, Issue:1 Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Cross-Sectional Studie	2013
Valproate-induced hyperammonemic encephalopathy followed by benzodiazepine withdrawal in a patient with schizoaffective disorder: a differential diagnosis. The Journal of neuropsychiatry and clinical neurosciences, 2013,Summer, Volume: 25, Issue:3 Topics: Anticonvulsants; Benzodiazepines; Delta Rhythm; Diagnosis, Differential; Electroencephalography; Hum	2013
Concordant response to pharmacotherapy in monozygotic twins with schizoaffective disorder. European review for medical and pharmacological sciences, 2013, Volume: 17, Issue:23 Topics: Affect; Alopecia; Antipsychotic Agents; Diseases in Twins; Drug Therapy, Combination; Emotions; Huma	2013
An atypical case of neuroleptic malignant syndrome precipitated by valproate. BMJ case reports, 2014, Mar-06, Volume: 2014 Topics: Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Benzothiazoles; Dopamine Agonists; Drug Ther	2014
Increased platelet intracellular calcium ion concentration is specific to bipolar disorder. Journal of affective disorders, 2014, Volume: 164 Topics: Adult; Antipsychotic Agents; Biomarkers; Bipolar Disorder; Blood Platelets; Calcium; Case-Control St	2014
Phosphorylation of transcription factor specificity protein 4 is increased in peripheral blood mononuclear cells of first-episode psychosis. PloS one, 2015, Volume: 10, Issue:4 Topics: Adolescent; Adult; Animals; Antipsychotic Agents; Benzodiazepines; Cells, Cultured; Cross-Sectional	2015
Reversible weakness and encephalopathy while on long-term valproate treatment due to carnitine deficiency. BMJ case reports, 2015, Sep-02, Volume: 2015 Topics: Adult; Antimanic Agents; Brain Diseases; Cardiomyopathies; Carnitine; Female; Humans; Hyperammonemia	2015
Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder. Journal of psychiatric practice, 2016, Volume: 22, Issue:3 Topics: Adult; Antimanic Agents; Antipsychotic Agents; Blood Glucose; Body Mass Index; Cross-Sectional Studi	2016
Valproate induced cerebellar atrophy presenting as movement disorder. Schizophrenia research, 2017, Volume: 184 Topics: Adult; Anticonvulsants; Atrophy; Cerebellum; Electroencephalography; Epilepsy, Tonic-Clonic; Female;	2017
Protection against hormone-mediated mood symptoms. Archives of women's mental health, 2017, Volume: 20, Issue:2 Topics: Affect; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Lithium; Lurasidone Hydrochloride; M	2017
Valproate-induced encephalopathy in a comorbid elderly woman. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2017, Volume: 17, Issue:3 Topics: Anticonvulsants; Brain Diseases; Comorbidity; Female; Humans; Hyperammonemia; Lethargy; Middle Aged;	2017
Clozapine-Valproate Adverse Drug Reactions and the Need for a Clozapine Rechallenge Case File. The primary care companion for CNS disorders, 2017, Jan-05, Volume: 19, Issue:1 Topics: Acute Kidney Injury; Antimanic Agents; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; H	2017
Toxic interaction between valproate and oxcarbazepine: a case detected by the free valproate level. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:4 Topics: Anticonvulsants; Antimanic Agents; Carbamazepine; Drug Interactions; Drug Therapy, Combination; Fema	2008
A mutation in the calreticulin gene promoter in a family case of schizoaffective disorder leads to its aberrant transcriptional activation. Brain research, 2008, Nov-06, Volume: 1239 Topics: Adolescent; Adult; Animals; Calbindin 2; Cells, Cultured; Central Nervous System Agents; Cerebral Co	2008
Patterns of antiepileptic drug overdose differ between men and women: admissions to the Edinburgh Poisons Unit, 2000-2007. QJM : monthly journal of the Association of Physicians, 2009, Volume: 102, Issue:1 Topics: Adult; Anticonvulsants; Carbamazepine; Drug Overdose; Female; Humans; Lamotrigine; Male; Middle Aged	2009
Adjunctive medication effects may increase risk for neutropenia. The American journal of psychiatry, 2008, Volume: 165, Issue:12 Topics: Antipsychotic Agents; Chemotherapy, Adjuvant; Clozapine; Drug Administration Schedule; Humans; Neutr	2008
Septo-optic dysplasia and psychiatric disorders: a case report. Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, 2008, Volume: 21, Issue:4 Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Depressive Disorder; Female; Humans; Magnet	2008
The incidence and characteristics of clozapine- induced fever in a local psychiatric unit in Hong Kong. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2008, Volume: 53, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder;	2008
Valproic acid-induced myopathy in a patient with schizoaffective disorder. Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:4 Topics: Aged, 80 and over; Antimanic Agents; Drug Interactions; Female; Humans; Muscular Diseases; Polypharm	2009
An initial report of a new biological marker for bipolar disorder: P85 evoked brain potential. Bipolar disorders, 2009, Volume: 11, Issue:6 Topics: Acoustic Stimulation; Adult; Antimanic Agents; Biomarkers; Bipolar Disorder; Electroencephalography;	2009
Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder. Therapeutic drug monitoring, 2009, Volume: 31, Issue:6 Topics: Adult; Aging; Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzo	2009
Post-ictal psychosis in adolescent Niemann-Pick disease type C. Journal of inherited metabolic disease, 2010, Volume: 33 Suppl 3 Topics: Adolescent; Age Factors; Anticonvulsants; Cells, Cultured; Cholesterol Esters; Esterification; Fibro	2010
The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. Clinical neurology and neurosurgery, 2010, Volume: 112, Issue:5 Topics: Aged; Antipsychotic Agents; Cinnarizine; Cohort Studies; Diagnosis, Differential; Female; Flunarizin	2010
[Psychotic disorder revealing epilepsy linked to a dysembryoma of the left hippocampus]. Revue neurologique, 2011, Volume: 167, Issue:3 Topics: Acute Disease; Adult; Anticonvulsants; Antipsychotic Agents; Diagnosis, Differential; Electroencepha	2011
Use of mood stabilizers for hospitalized psychotic and bipolar disorder patients. International clinical psychopharmacology, 2011, Volume: 26, Issue:2 Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dr	2011
Folie à deux: double case-report of shared delusions with a fatal outcome. La Clinica terapeutica, 2011, Volume: 162, Issue:1 Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Clozapine; Combined Modality Therapy;	2011
Vulnerability of an epileptic case to psychosis: sodium valproate with lamotrigine, forced normalization, postictal psychosis or all? Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2012, Volume: 33, Issue:5 Topics: Adult; Age of Onset; Anticonvulsants; Child; Drug Therapy, Combination; Electroencephalography; Epil	2012
Postictal psychosis in a 3-year-old child. Journal of child neurology, 2012, Volume: 27, Issue:10 Topics: Child, Preschool; Electroencephalography; Female; Humans; Psychotic Disorders; Seizures, Febrile; Va	2012
A case of valproate-induced encephalopathy. The Australian and New Zealand journal of psychiatry, 2012, Volume: 46, Issue:12 Topics: Ammonia; Antimanic Agents; Brain Diseases, Metabolic; Female; Humans; Hyperammonemia; Middle Aged; P	2012
Antipsychotic and sedative effects of the leaf extract of Crassocephalum bauchiense (Hutch.) Milne-Redh (Asteraceae) in rodents. Journal of ethnopharmacology, 2012, Aug-30, Volume: 143, Issue:1 Topics: Animals; Antipsychotic Agents; Apomorphine; Asteraceae; Behavior, Animal; Body Temperature; Brain; C	2012
Stupor due to possible interaction between Lorazepam and valproic acid: report of two cases. Turk psikiyatri dergisi = Turkish journal of psychiatry, 2012,Winter, Volume: 23, Issue:4 Topics: Anti-Anxiety Agents; Anticonvulsants; Diagnosis, Differential; Drug Interactions; Drug Therapy, Comb	2012
Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice. BMC psychiatry, 2012, Dec-17, Volume: 12 Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Australia; B	2012
Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. Clinical therapeutics, 2002, Volume: 24, Issue:10 Topics: Adult; Anticonvulsants; Antimanic Agents; Body Mass Index; Body Weight; Data Collection; Female; Fru	2002
Oxcarbazepine vs. valproate in the treatment of mood and schizoaffective disorders. The international journal of neuropsychopharmacology, 2003, Volume: 6, Issue:4 Topics: Adult; Akathisia, Drug-Induced; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Brief Psychiatr	2003
Valproic Acid and hypersensitivity syndrome. The American journal of psychiatry, 2004, Volume: 161, Issue:3 Topics: Anticonvulsants; Bipolar Disorder; Drug Eruptions; Drug Hypersensitivity; Drug Therapy, Combination;	2004
QTc prolongation in multiple drug overdose. Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:3 Topics: Adult; Bupropion; Drug Overdose; Fluoxetine; Humans; Long QT Syndrome; Male; Piperazines; Psychotic	2004
Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels. The Journal of clinical psychiatry, 2004, Volume: 65, Issue:6 Topics: Affect; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug Therapy, Combin	2004
Pharmacokinetics of aripiprazole and concomitant lithium and valproate. Journal of clinical pharmacology, 2005, Volume: 45, Issue:1 Topics: Adult; Aripiprazole; Drug Therapy, Combination; Humans; Lithium; Male; Middle Aged; Piperazines; Psy	2005
Acute psychosis with a mediastinal carcinoma metastasis. Medical science monitor : international medical journal of experimental and clinical research, 2005, Volume: 11, Issue:1 Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Humans; Male; Mediastinal Neoplasms; Middle Ag	2005
In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proceedings of the National Academy of Sciences of the United States of America, 2005, Feb-08, Volume: 102, Issue:6 Topics: Adult; Aged; Antipsychotic Agents; Biomarkers; Cell Adhesion Molecules, Neuronal; Cerebral Cortex; D	2005
Co-existence of lycanthropy and Cotard's syndrome in a single case. Acta psychiatrica Scandinavica, 2005, Volume: 111, Issue:3 Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Combined Modality Therapy; Diagnostic and Statistical	2005
Neurotoxicity associated with free valproic acid. The American journal of psychiatry, 2005, Volume: 162, Issue:4 Topics: Antimanic Agents; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Psychotic Disorders; Valproic	2005
A psychotic episode associated with the Atkins diet in a patient with bipolar disorder. Bipolar disorders, 2005, Volume: 7, Issue:3 Topics: Antimanic Agents; Anxiety; Bipolar Disorder; Confusion; Diet Fads; Humans; Ketosis; Male; Middle Age	2005
High vulnerability to acute dystonic reactions: a case of antipsychotic exposure and uncontrolled seizure activity. Progress in neuro-psychopharmacology & biological psychiatry, 2005, Volume: 29, Issue:5 Topics: Anticonvulsants; Antipsychotic Agents; Chronic Disease; Cytochrome P-450 CYP2D6; Dibenzothiazepines;	2005
A case of delirium and subsequent pancytopenia associated with the oral loading of valproic acid. The Journal of clinical psychiatry, 2005, Volume: 66, Issue:6 Topics: Administration, Oral; Anticonvulsants; Delirium; Dose-Response Relationship, Drug; Drug Administrati	2005
Worsening of psychotic symptoms in schizophrenia with addition of lamotrigine: a case report. Schizophrenia research, 2005, Oct-15, Volume: 78, Issue:2-3 Topics: Adult; Antipsychotic Agents; Brain; Clozapine; Drug Therapy, Combination; Female; Humans; Lamotrigin	2005
Pisa syndrome in a patient in a wheelchair taking valproic acid. The American journal of psychiatry, 2006, Volume: 163, Issue:2 Topics: Aged; Anticonvulsants; Antipsychotic Agents; Drug Therapy, Combination; Dystonia; Humans; Male; Psyc	2006
The rational use of medications in acute psychotic presentations -- the case for less is more. Journal of psychiatry & neuroscience : JPN, 2006, Volume: 31, Issue:3 Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clopenthixol; Humans	2006
Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:5 Topics: Adult; Aggression; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Case-Control Studies; Dr	2006
Sporadic case of spinocerebellar ataxia type 17: treatment observations for managing urinary and psychotic symptoms. Movement disorders : official journal of the Movement Disorder Society, 2007, Feb-15, Volume: 22, Issue:3 Topics: Anticonvulsants; Electromyography; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Psychotic	2007
Oral contraceptive administration prevents relapse of periodic psychosis with hyperprolactinemia. Psychiatry and clinical neurosciences, 2007, Volume: 61, Issue:1 Topics: Adult; Antimanic Agents; Contraceptives, Oral, Hormonal; Female; Humans; Hyperprolactinemia; Menstru	2007
Characteristics of psychotic patients with foreign accent syndrome. The Journal of neuropsychiatry and clinical neurosciences, 2007,Winter, Volume: 19, Issue:1 Topics: Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; C	2007
Glycopyrrolate for clozapine-induced sialorrhea. Progress in neuro-psychopharmacology & biological psychiatry, 2007, Oct-01, Volume: 31, Issue:7 Topics: Adult; Antimanic Agents; Antipsychotic Agents; Clozapine; Fluphenazine; Glycopyrrolate; Humans; Male	2007
Bipolar pharmacotherapy and suicidal behavior. Part I: Lithium, divalproex and carbamazepine. Journal of affective disorders, 2007, Volume: 103, Issue:1-3 Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Female; Hospitalization; Humans;	2007
Cervical dystonia due to interaction of valproic acid and quetiapine. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:4 Topics: Antimanic Agents; Antipsychotic Agents; Dibenzothiazepines; Humans; Male; Middle Aged; Psychotic Dis	2007
Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. Journal of child and adolescent psychopharmacology, 2007, Volume: 17, Issue:5 Topics: Adolescent; Adult; Aging; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Body Weight; Chil	2007
[Lithium intoxications at normal serum levels]. Psychiatrische Praxis, 2008, Volume: 35, Issue:4 Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Delirium; Dose-Response Relationship, Drug	2008
Alternative therapeutic approaches to the treatment of acute phases of endogenous psychoses. Homeostasis in health and disease : international journal devoted to integrative brain functions and homeostatic systems, 1991, Volume: 33, Issue:5-6 Topics: Acute Disease; Anticonvulsants; Benzodiazepines; Carbamazepine; Humans; Hypnotics and Sedatives; Psy	1991
Diurnal fluctuation of serum level of sodium valproate and interaction with neuroleptics. Folia psychiatrica et neurologica japonica, 1980, Volume: 34, Issue:3 Topics: Adolescent; Adult; Antipsychotic Agents; Circadian Rhythm; Drug Interactions; Epilepsy; Female; Huma	1980
Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo. Acta psychiatrica Scandinavica, 1983, Volume: 67, Issue:3 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Biperiden; Double-Blind Method; Drug Therapy, Combina	1983
New drugs for mania? The British journal of psychiatry : the journal of mental science, 1983, Volume: 142 Topics: Affective Disorders, Psychotic; Bipolar Disorder; Humans; Propranolol; Psychotic Disorders; Valproic	1983
Valproic acid amide as a prophylactic agent in affective and schizoaffective disorders. Psychopharmacology bulletin, 1984,Winter, Volume: 20, Issue:1 Topics: Adult; Bipolar Disorder; Humans; Middle Aged; Mood Disorders; Psychotic Disorders; Recurrence; Valpr	1984
Psychiatric manifestations of temporal lobe epilepsy in older adults. The Journal of neuropsychiatry and clinical neurosciences, 1995,Spring, Volume: 7, Issue:2 Topics: Aged; Dementia; Depressive Disorder; Diagnosis, Differential; Electroencephalography; Epilepsy, Temp	1995
A clinically significant interaction between clozapine and valproate. Journal of clinical psychopharmacology, 1995, Volume: 15, Issue:2 Topics: Adult; Arousal; Bipolar Disorder; Clozapine; Confusion; Dose-Response Relationship, Drug; Drug Inter	1995
Hypothesized interaction between valproic acid and warfarin. Journal of clinical psychopharmacology, 1995, Volume: 15, Issue:2 Topics: Aged; Blood Coagulation Tests; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug	1995
Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders. Journal of clinical psychopharmacology, 1994, Volume: 14, Issue:5 Topics: Bipolar Disorder; Brain Damage, Chronic; Cohort Studies; Double-Blind Method; Electroencephalography	1994
Concurrent use of clozapine and valproate in affective and psychotic disorders. The Journal of clinical psychiatry, 1994, Volume: 55, Issue:6 Topics: Adult; Clozapine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Incidence	1994
Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. Journal of clinical psychopharmacology, 1994, Volume: 14, Issue:1 Topics: Adult; Bipolar Disorder; Carbamazepine; Dose-Response Relationship, Drug; Drug Therapy, Combination;	1994
Valproate as a loading treatment in acute mania. Neuropsychobiology, 1993, Volume: 27, Issue:3 Topics: Acute Disease; Adult; Bipolar Disorder; Female; Humans; Male; Middle Aged; Psychotic Disorders; Valp	1993
Divalproex sodium in the treatment of refractory affective disorders. The Journal of clinical psychiatry, 1993, Volume: 54, Issue:10 Topics: Adult; Aged; Bipolar Disorder; Carbamazepine; Depressive Disorder; Drug Therapy, Combination; Female	1993
Trends in pharmacotherapy of Schizoaffective and bipolar affective disorders: a 5-year naturalistic study. The American journal of psychiatry, 1996, Volume: 153, Issue:5 Topics: Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Drug Therapy, Combination; Drug Utilizati	1996
The use of valproate in an elderly population with affective symptoms. The Journal of clinical psychiatry, 1996, Volume: 57, Issue:6 Topics: Affective Disorders, Psychotic; Age Factors; Aged; Antimanic Agents; Comorbidity; Depressive Disorde	1996
Medication optimization during clozapine treatment. The Journal of clinical psychiatry, 1996, Volume: 57, Issue:7 Topics: 1-Naphthylamine; Adult; Clozapine; Drug Therapy, Combination; Humans; Lithium; Male; Obsessive-Compu	1996
Valproate treatment of alcohol withdrawal and mania. The American journal of psychiatry, 1996, Volume: 153, Issue:9 Topics: Adult; Alcoholism; Bipolar Disorder; Ethanol; Humans; Male; Psychotic Disorders; Substance Withdrawa	1996
Valproate and neuroleptic medication. The British journal of psychiatry : the journal of mental science, 1997, Volume: 170 Topics: Adult; Antimanic Agents; Antipsychotic Agents; Drug Resistance; Drug Therapy, Combination; Female; H	1997
Catatonia-like events after valproic acid with risperidone and sertraline. Neuropsychiatry, neuropsychology, and behavioral neurology, 1998, Volume: 11, Issue:3 Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Catatonia; Drug Interactions; D	1998
Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health. The Psychiatric quarterly, 1998,Winter, Volume: 69, Issue:4 Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug Utilizatio	1998
Risperidone as an adjunct to valproic acid. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1999, Volume: 44, Issue:2 Topics: Antimanic Agents; Antipsychotic Agents; Drug Therapy, Combination; Humans; Male; Middle Aged; Psycho	1999
Valproate-induced hyperammonemia in the psychiatric setting: 2 cases. The Journal of clinical psychiatry, 1999, Volume: 60, Issue:8 Topics: Adult; Ammonia; Anticonvulsants; Bipolar Disorder; Humans; Male; Mental Disorders; Middle Aged; Psyc	1999
Efficacy of divalproex therapy for schizoaffective disorder. Journal of clinical psychopharmacology, 2000, Volume: 20, Issue:5 Topics: Adult; Anticonvulsants; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Psychot	2000
Stevens-Johnson syndrome associated with concomitant use of lamotrigine and valproic acid. Journal of the American Academy of Dermatology, 2000, Volume: 43, Issue:5 Pt 2 Topics: Adult; Anticonvulsants; Antimanic Agents; Drug Therapy, Combination; Female; Humans; Lamotrigine; Ps	2000
Treatment of schizoaffective disorder with divalproex sodium. Schizophrenia research, 2000, Nov-30, Volume: 46, Issue:1 Topics: Adolescent; Adult; Aged; Antimanic Agents; Female; Humans; Male; Middle Aged; Psychotic Disorders; V	2000
Pharmacologic treatment of patients hospitalized with the diagnosis of schizoaffective disorder. The Journal of clinical psychiatry, 2001, Volume: 62, Issue:1 Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Drug Therapy, Combin	2001
Retrospective analysis of serum valproate levels and need for an antidepressant drug. Pharmacotherapy, 2001, Volume: 21, Issue:7 Topics: Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Chi-Square Distribution; Female; H	2001
Does EEG predict response to valproate versus lithium in patients with mania? Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2001, Volume: 13, Issue:2 Topics: Acute Disease; Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Brain; Electroencephalogr	2001
Pharmacologic treatment of hospitalized patients with schizoaffective disorder. Psychiatric services (Washington, D.C.), 2002, Volume: 53, Issue:1 Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Drug Therapy, Combination; Female; Hospitalizati	2002
Divalproex as a calmative adjunct for aggressive schizophrenic patients. The Journal of the Kentucky Medical Association, 2002, Volume: 100, Issue:1 Topics: Adult; Aggression; Antipsychotic Agents; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans;	2002
Divalproex in the management of neuropsychiatric complications of remote acquired brain injury. The Journal of neuropsychiatry and clinical neurosciences, 2002,Spring, Volume: 14, Issue:2 Topics: Adolescent; Adult; Anticonvulsants; Bipolar Disorder; Brain Injuries; Child; Child, Preschool; Depre	2002
Valproic acid and risperidone. Journal of the American Academy of Child and Adolescent Psychiatry, 2002, Volume: 41, Issue:6 Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Drug Interactions; Epilepsy; Female; Humans; Psyc	2002
Valproate treatment of older psychotic patients with organic mental syndromes and behavioral dyscontrol. Journal of the American Geriatrics Society, 1992, Volume: 40, Issue:9 Topics: Age Factors; Aged; Aggression; Comorbidity; Drug Therapy, Combination; Female; Humans; Neurocognitiv	1992
Anticonvulsant treatment of psychoses. The Australian and New Zealand journal of psychiatry, 1990, Volume: 24, Issue:2 Topics: Adult; Chronic Disease; Female; Humans; Male; Neurocognitive Disorders; Psychotic Disorders; Schizop	1990
Therapeutic levels of valproate for psychosis. Psychopharmacology bulletin, 1990, Volume: 26, Issue:2 Topics: Humans; Psychotic Disorders; Valproic Acid	1990
Neuroleptic-valproic acid combination in treatment of psychotic symptoms: a three-case report. Journal of clinical psychopharmacology, 1989, Volume: 9, Issue:1 Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Female; Hallucinations; Humans; Male; Middle	1989
Forced normalization. Acute psychosis after seizure control in seven patients. Archives of neurology, 1987, Volume: 44, Issue:3 Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Haloperidol; Humans; Male; Psychotic Disord	1987
[Personal experience with the prophylactic effect of dipropylacetamide]. Ceskoslovenska psychiatrie, 1988, Volume: 84, Issue:1 Topics: Adult; Bipolar Disorder; Depressive Disorder; Female; Humans; Male; Middle Aged; Psychotic Disorders	1988

valproic acid and Psychoses